Vaccine for mosquito-borne infection shows promise in test

Share with others:


Print Email Read Later

MINNEAPOLIS — A novel vac­cine de­vel­oped by U.S. gov­ern­ment re­search­ers is show­ing prom­ise against chikun­gunya, a de­bil­i­tat­ing mos­quito-borne vi­rus that started spread­ing this sum­mer in the south­ern United States.

The vi­rus has sick­ened mil­lions of peo­ple in Africa and Asia, where it is en­demic, and slammed into the Ca­rib­bean and South Amer­ica in the past year with an es­ti­mated 165,000 cases. The in­fec­tion trig­gers a high fe­ver and mal­aise, with the vi­rus of­ten pen­e­trat­ing the joints and caus­ing se­vere ar­thri­tis pain that can last for months. There is no treat­ment.

The ex­per­i­men­tal im­mu­ni­za­tion, given in three in­jec­tions at vary­ing doses to 25 healthy vol­un­teers, trig­gered an im­mune re­sponse sim­i­lar to pa­tients who re­cov­ered from the in­fec­tion, ac­cord­ing to the study pub­lished Thurs­day in the jour­nal Lan­cet. Most re­search­ers be­lieve that pa­tients who re­cover from the in­fec­tion won’t get sick again, though more in­ves­ti­ga­tion is needed, said al­ler­gist-im­mu­nol­o­gist Julie Ledger­wood, a se­nior study au­thor.

The strength of the re­sponse “is why we are so op­ti­mis­tic about the vac­cine,” Dr. Ledger­wood, chief of the vac­cine re­search cen­ter at the Na­tional In­sti­tute of Al­lergy and In­fec­tious Dis­eases, said in a phone in­ter­view. “At all three doses, the sub­jects tol­er­ated the vac­cine well, a very im­por­tant point in a first in hu­man study.”

While chikun­gunya ini­tially emerged in Tan­za­nia in 1953, the first four in­fec­tions ac­quired in the United States started last month in Flor­ida. The mos­qui­toes that spread the dis­ease have re­cently been found from Vir­ginia to Flor­ida, sweep­ing across the south­ern United States to Cal­i­for­nia. His­tor­i­cally, they have been spot­ted as far north as New York and Iowa.

More work must be done be­fore the im­mu­ni­za­tion is of­fered to a wider group of peo­ple. It costs $200 mil­lion to $500 mil­lion to de­velop a new vac­cine, which can be a chal­lenge if the mar­ket isn’t large enough to jus­tify the in­vest­ment, said Ann M. Pow­ers, of the U.S. Centers for Dis­ease Con­trol and Preven­tion’s di­vi­sion of vec­tor-borne dis­eases in Fort Collins, Colo. Re­search­ers should con­tinue work­ing on this and other vac­cines for chikun­gunya since the vi­rus can blaze through un­pro­tected groups of peo­ple, sick­en­ing as much as 63 per­cent of a lo­cal group within months, she wrote in an ed­i­to­rial.

The vac­cine is crafted from pro­teins found on the out­side en­ve­lope of the vi­rus, par­ti­cles that ac­ti­vate the im­mune sys­tem with­out car­ry­ing the ge­netic ma­terial needed to trig­ger an in­fec­tion. All 25 vol­un­teers pro­duced an­ti­bod­ies to neu­tral­ize the vi­rus af­ter get­ting the in­jec­tions, with a sig­nifi­cant boost af­ter the third shot, the study found.

The an­ti­bod­ies pro­duced to fight an in­fec­tion re­mained for at least 11 months af­ter the fi­nal vac­ci­na­tion, sug­gest­ing that the pro­tec­tion may be long-last­ing, the re­search­ers said.

The Na­tional In­sti­tutes of Health has re­ceived one li­cense ap­pli­ca­tion from a po­ten­tial part­ner, Dr. Ledger­wood said. The agency is com­mit­ted to con­tin­ued de­vel­op­ment of the vac­cine, and a part­ner­ship would al­low the re­search­ers to go fur­ther, she said. Ad­di­tional work on the safety and po­tency of the vac­cine is nec­es­sary be­fore large-scale tri­als could be done, she said.

There have been more than 570,000 sus­pected cases in the Amer­i­cas since the vi­rus first ap­peared in the Western Hemi­sphere in late 2013, ac­cord­ing to the NIH. More than 500 cases have been re­ported in the con­ti­nen­tal United States; al­most all in­volved trav­el­ers who brought the vi­rus with them.



Advertisement
Advertisement
Advertisement

You have 2 remaining free articles this month

Try unlimited digital access

If you are an existing subscriber,
link your account for free access. Start here

You’ve reached the limit of free articles this month.

To continue unlimited reading

If you are an existing subscriber,
link your account for free access. Start here